Program
Prednisolone
Also written as “Desloratadine + Prednisolone”, “prednisolone” and “Desloratadine , Prednisolone”.
Its studies are mostly in Prostatic Neoplasms · Arthritis, Rheumatoid · Rhinitis, Allergic · Asthma · Pulmonary Disease, Chronic Obstructive, led by 13 companies.
Drug pagePrednisolone: every studyMany companies study it; this page follows only the 26 they lead. All 247 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 50 open or running | phase 3since Mar 11, 2010 | Aug 24, 2005 | none ahead |
| Sanofiits history only | 50 open or running | phase 4since Feb 26, 2014 | Jul 9, 2007 | none ahead |
| EMSits history only | 40 open or running | phase 3since Sep 5, 2011 | Sep 5, 2011 | none ahead |
| Astellas Pharma | 32 open or running | phase 2since May 27, 2025 | Jun 26, 2024 | Oct 31, 2027phase 2 · NCT07052929 |
| Adapt Produtos Oftalmológicos Ltda.its history only | 10 open or running | phase 3since Mar 22, 2011 | Mar 22, 2011 | none ahead |
| Bausch Health Companiesits history only | 10 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Biogenits history only | 10 open or running | phase 4since Jul 29, 2010 | Jul 29, 2010 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since Jan 3, 2019 | Jan 3, 2019 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Dec 13, 2021 | Dec 13, 2021 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Nov 7, 2012 | Nov 7, 2012 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Sep 6, 2013 | Sep 6, 2013 | none ahead |
| Ultragenyx Pharmaceuticalits history only | 10 open or running | phase 3since Jul 14, 2021 | Jul 14, 2021 | none ahead |
| Zalicusits history only | 10 open or running | phase 2since Jun 7, 2011 | Jun 7, 2011 | none ahead |
Also a collaborator on its studies: Elan Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Astellas Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2024First study: phase 1 study in Friedreich AtaxiaFirst studyNCT06483802
- May 27, 2025Phase 2 study in Prostatic NeoplasmsNCT07005154 · 218 planned · United States, China, France and more
- Jun 30, 2025Phase 2 study in Myopathies, Structural, CongenitalNCT07052929 · 9 planned · United States, Canada
Ahead
- Oct 31, 2027Primary completion: phase 2 study in Myopathies, Structural, CongenitalNCT07052929
- May 31, 2032Primary completion: phase 2 study in Prostatic NeoplasmsNCT07005154
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
All 3 Astellas Pharma leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07052929Myopathies, Structural, Congenital · United States, Canada | 2 | Recruiting | Oct 31, 2027 | 9 |
| NCT07005154Prostatic Neoplasms · United States, China, France and more | 2 | Recruiting | May 31, 2032 | 218 |
| NCT06483802Friedreich Ataxia | 1 | Withdrawn | Oct 22, 2025 | 0 |
How it is read
Names in the registry
- “Prednisolone”, 17 entries
- “Desloratadine + Prednisolone”, 3 entries
- “prednisolone”, 3 entries
- “Desloratadine , Prednisolone”, 1 entry
- “Oral prednisolone”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 7 studies
- Arthritis, Rheumatoid, 4 studies
- Rhinitis, Allergic, 3 studies
- Asthma, 3 studies
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.